Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.34 |
| ▸ | RXRG | P48443 | 6/20 | 0.34 |
| ▸ | RXRB | P28702 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HNF4A | P41235 | 4/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | RARG | P13631 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053364 | 1.00 | RXRA (0.34) | RXRARXRGRXRBHPGDTSHR | |
| SCHEMBL6542944 | 0.88 | RXRA (0.33) | RXRARXRGRXRBRARARARB | |
| SCHEMBL6542941 | 0.88 | RXRA (0.33) | RXRARXRGRXRBRARARARB | |
| SCHEMBL6541508 | 0.84 | HPGD (0.41) | RXRARXRGRXRBHPGDTSHR | |
| SCHEMBL6541500 | 0.84 | HPGD (0.41) | RXRARXRGRXRBHPGDTSHR | |
| SCHEMBL6542673 | 0.82 | RXRA (0.37) | RXRARXRGRXRBRARARARB | |
| SCHEMBL6542671 | 0.82 | RXRA (0.37) | RXRARXRGRXRBRARARARB | |
| SCHEMBL5489249 | 0.77 | GSK3A (0.44) | RXRAHPGD | |
| SCHEMBL14492767 | 0.77 | GSK3A (0.44) | RXRAHPGD | |
| SCHEMBL5489251 | 0.77 | GSK3A (0.44) | RXRAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RXRA 793/4885RXRG 744/4885RXRB 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.